Jun 18, 2019 - Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Apr 26, 2019 - Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
Apr 26, 2019 - SGEN earnings call for the period ending March 31, 2019.
Apr 26, 2019 - Seattle Genetics, Inc. (NASDAQ:SGEN) Q1 2019 Earnings Conference Call April 25, 2019 17:00 ET Company Participants Peggy Pinkston - VP, IR Clay Siegall - President & CEO Roger Dansey - Chief Medic
Apr 25, 2019 - Top Gainers: EHTH +12.2%. MAT +11.9%. F +7.9%. PRO +7.6%. GRUB +5.1%.Top Losers: ATEN -15.8%. INTC -7.6%. BEAT -6.9%. PFPT -6.3%. SGEN -5.2%.
Apr 25, 2019 - The
S&P 500 (-0.04%) finished fractionally lower on Thursday, although strong
earnings reports from
Apr 18, 2019 - Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Mar 29, 2019 - Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.
Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.